Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up

Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up

BackgroundDiscontinuation of antiviral therapy in chronic hepatitis B (CHB) patients leads to a higher hepatitis B surface antigen (HBsAg) loss; yet, clinical relapse (CR) may occur. SCALE-B score was developed to predict off-treatment CR; however, validation of SCALE-B beyond a 48-week follow-up is...

Full description

Bibliographic Details
Main Authors: Apichat Kaewdech, Suraphon Assawasuwannakit, Pimsiri Sripongpun, Naichaya Chamroonkul, Pisit Tangkijvanich, Teerha Piratvisuth
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Medicine
Subjects:
clinical relapse (CR)
hepatitis B core-related antigen (HBcrAg)
hepatitis B surface antigen (HBsAg)
hepatitis B virus ribonucleic acid (HBV RNA)
nucleos(t)ide analogues (NAs)
cessation
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.859430/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.859430/full

Similar Items